DGAP-Adhoc ​​​​​​​PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION

Nachrichtenquelle: EQS Group AG
29.01.2021, 11:20  |  190   |   |   

DGAP-Ad-hoc: PAION AG / Key word(s): Miscellaneous
​​​​​​​PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION

29-Jan-2021 / 11:20 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION

- Positive CHMP opinion based on the data from a comprehensive clinical program in procedural sedation in adult patients undergoing bronchoscopy or colonoscopy

- Final decision on MAA expected in the first half of 2021

Aachen (Germany), 29 January 2021 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Byfavo(R) (remimazolam) in procedural sedation in adult patients.

The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorization Application (MAA) for Byfavo(R) in the EU (including European Economic Area (EEA) countries) is expected in the first half of 2021. The UK Medicines & Healthcare products Regulatory Agency (MHRA) will also consider the positive opinion for a potential approval in the United Kingdom.

End of inside information

 


Information and Explanation of the Issuer to this News:

The positive CHMP opinion for Byfavo(R) (remimazolam) is based on the clinical program in procedural sedation in adult patients undergoing bronchoscopy or colonoscopy. Remimazolam was approved in China and in the U.S. in July 2020 for the induction and maintenance of procedural sedation in adults.

Remimazolam is also in development for general anesthesia in Europe, and was approved in Japan and South Korea for general anesthesia. Assuming approval in procedural sedation by the European Commission, PAION plans to submit an extension of the marketing authorization for remimazolam for general anesthesia based on the recently announced positive EU Phase III data.

Seite 1 von 4


Diesen Artikel teilen

Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc ​​​​​​​PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION DGAP-Ad-hoc: PAION AG / Key word(s): Miscellaneous ​​​​​​​PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION 29-Jan-2021 / 11:20 CET/CEST Disclosure of an inside information acc. to Article …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel